Most Read Articles
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.

Psychoactive medication use frequently continued beyond discharge

03 Dec 2020
MDMA is the main psychoactive ingredient in the recreational drug ecstasy.

A pilot study of stewardship has found that the use of psychoactive medications (PMs) is commonly continued during transitions of care, often without knowledge of the initial indication.

“PMs are frequently administered in the intensive care unit (ICU) to provide comfort,” the investigators said. “Interventions focused on preventing their continuation after the acute phase of illness are needed.”

This single-centre, prospective, observational study sought to determine the frequency that patients with ICU-initiated PM were continued upon ICU and hospital discharge. Sixty consecutive adult ICU patients who received scheduled PM were included in the analysis.

The investigators then recorded the frequency of PM continued at ICU and hospital discharge. A pharmacist contacted the patient’s primary treatment team within 72 hours of ICU discharge to establish a rationale for continued use or to suggest treatment cessation.

Seventy-two percent of the 60 patients included continued using PM at ICU discharge, while 30 percent did so at hospital discharge. The pharmacist contacted 40 percent of treatment teams after ICU discharge, and this intervention led to PM discontinuation in half of the patients (50 percent).

Notably, the indication of 41 percent of patients’ PM after ICU discharge was either unknown by the non-ICU care team or incorrect. Medical ICU patients or those transferred to an outside facility were more likely to continue the use of PM at hospital discharge.

“Future studies should establish effective PM stewardship methods,” the investigators suggested.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.